In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Cytek Biosciences’ current price exceeds its high-confidence weighted fair value by over 20%, indicating potential overvaluation. Negative profitability and efficiency scores, alongside significant downside risk in Monte Carlo scenarios, highlight elevated investment risk. High liquidity and growth scores provide some balance but overall financial health signals caution.